Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

03/16
2017

Frontline Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment

Announcing the investigator initiated trial Pembro IST is anticipated to expand enrollment to UCLA satellite sites. Pembrolizumab is an antibody that inhibits the PD-1/PD-L1 immune checkpoint and allows the immune system to des…

03/14
2017

Advice From Patients On A Study’s Design Makes For Better Science

Clinical Trials News:  NCI-MATCH trial upends the normal way of classifying cancers for treatment: Instead of categorizing malignancies by the organ where they first appear, this method of sorting focuses on particular mutations in the ge…

03/7
2017

Update: CRISPR

Scientists say they’ll someday be able to use CRISPR to fight cancer and maybe even bring animals back from the dead. Read the story: http://www.radiolab.org/story/update-crispr/…

02/14
2017

Trial for Patients Doing Well on Nivolumab Expands to UCLA

The Checkmate 384 study will is now available at UCLA sites in addition to the sites already open in the TRIO-US network. This study is a dose frequency optimization trial of nivolumab in patients with Stage IIIB or Stage IV squa…

01/27
2017

Stand Up To Cancer Ushers In New Approach to Research with Calls by AACR for SU2C Dream Teams on “Interception” of Pancreas and Lung Cancers, Each Funded at $7 Million

Stand Up To Cancer (SU2C) broke new ground today when the American Association for Cancer Research (AACR), its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception…

01/27
2017

Advanced NSCLC Patients Live Longer When Treated, but Proportion of Untreated Patients Rising

Patients with advanced non-small cell lung cancer (NSCLC) who receive treatment live longer than those who remain untreated, but the proportion of NSCLC patients with advanced disease who don’t receive treatment has been rising in the Unit…

01/24
2017

Multimillion Dollar Grant Awarded from the National Cancer Institute for Translational Research at UCLA and in TRIO-US

The December, 2016 issue of  THORACIC ONCOLOGY TRANSLATIONAL RESEARCH AT UCLA & TRIO-US announces that the National Cancer Institute has awarded funding to study determinants of benefit from PD-1 inhibitors in patients at UCLA (includ…

01/10
2017

Personalized Medicine Impacting Study Conduct

“We are moving to an era where we use molecular analysis of patient samples either to enroll people in trials or understand how drugs work or don’t work,” said Ross Levine, M.D., a physician-scientist at the Memorial Slo…

12/20
2016

Immunotherapy Agent Improved Quality of Life in Lung Cancer Study

  There was a quality of life improvement for patients with non-small cell lung cancer who were treated with Keytruda compared to those who had standard chemotherapy, according to new data from the trial presented at the IASLC 17th Wo…

12/20
2016

Boehringer Ingelheim HCP Survey: Nearly 20% Of Newly Diagnosed Lung Cancer Patients Tested For EGFR Mutations At Risk Of Missing Out On Personalised Treatments For Their Disease

Recent international survey showed high global EGFR testing rates prior to first-line lung cancer therapy but highlighted a shortfall in the number of test results received before deciding on therapy. Nearly one in five patients are at r…